切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2013, Vol. 09 ›› Issue (04) : 492 -494. doi: 10.3877/cma.j.issn.1673-5250.2013.04.015

所属专题: 文献

论著

X射线损伤修复交叉互补基因1单核苷酸多态性与晚期宫颈癌TP化疗方案灵敏度的相关性研究
王一娜1,*,*(), 童亚非1   
  1. 1. 224000 江苏盐城,东南大学附属盐城医院
  • 收稿日期:2013-02-12 修回日期:2013-05-05 出版日期:2013-08-01
  • 通信作者: 王一娜

Correlation of the Sensitivity of TP Chemotherapy Regimens and X-Ray Cross Complementing Group 1 Gene Polymorphism in Advanced Cervical Cancer Patients

Yi-na WANG1(), Ya-fei TONG1   

  1. 1. Department of Gynecology and Obstetrics, Affiliated Yancheng Hospital of Southeast University Medical College, Yancheng 224001, Jiangsu Province, China
  • Received:2013-02-12 Revised:2013-05-05 Published:2013-08-01
  • Corresponding author: Yi-na WANG
  • About author:
    (Corresponding author: WANG Yi-na, Email: )
引用本文:

王一娜, 童亚非. X射线损伤修复交叉互补基因1单核苷酸多态性与晚期宫颈癌TP化疗方案灵敏度的相关性研究[J]. 中华妇幼临床医学杂志(电子版), 2013, 09(04): 492-494.

Yi-na WANG, Ya-fei TONG. Correlation of the Sensitivity of TP Chemotherapy Regimens and X-Ray Cross Complementing Group 1 Gene Polymorphism in Advanced Cervical Cancer Patients[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2013, 09(04): 492-494.

目的

探讨X射线损伤修复交叉互补基因1(XRCC1)单核苷酸多态性与晚期宫颈癌TP方案疗效的关系。

方法

收集2010年1月至2011年12月于本院化疗的晚期宫颈癌患者97例为研究对象,采用聚合酶链反应-限制性片段长度多态性技术(PCR-RFLP)检测其外周血DNA XRCC1 Codon 399位点多态性(本研究遵循的程序符合本院人体试验委员会制定的伦理学标准,得到该委员批准,并于受试者签署临床研究知情同意书)。采用紫杉醇+卡铂(TP)化疗方案,化疗3个疗程后评价其疗效,并分析化疗疗效与基因多态性的关系。

结果

本组97例患者中,疗效判定有效者为48例,无效为49例,总有效率为49.48%。携带XRCC1基因Codon 399 G/G基因型患者的化疗有效率为38.24%(13/34),G/A患者的化疗有效率为47.37%(18/38),A/A患者的化疗有效率为68.00%(17/25),G/G基因型和A/A基因型的化疗有效率比较,差异有统计学意义(P<0.05),其余两者间比较,差异无统计学意义(P>0.05)。3种不同的XRCC1 Codon 399单核苷酸多态型与晚期宫颈癌化疗疗效之间,存在正相关(r=0.9992,P<0.05)。

结论

XRCC1 Codon 399基因型可预测晚期宫颈癌TP方案化疗的疗效。

Objective

To study the correlation between single nucleotide polymorphism of X-ray cross complementing group 1(XRCC1) and chemotherapy sensitivity of the advanced cervical cancer patients with TP chemotherapy regimens (taxol+ carboplatin).

Methods

The XRCC1 polymorphism at 399 site was detected in 97 patients with advanced cervical cancer patients, who recruited into our hospital from January 2010 to December 2011, by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). They were treated with TP chemotherapy and evaluated before and after three periods of chemotherapy, and then the correlation of the sensitivity of chemotherapy with polymorphisms was analyzed. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Affiliated Yancheng Hospital of Southeast University Medical College. Informed consent was obtained from all participates' parents.

Results

The total effective rate was 49.48%(48/97). The effective rates of chemotherapy were 38.24%(13/34) in patients with the XRCC1 codon 399 G/G, 47.37%(18/38) in 399 G/A, and 68.00%(17/25) in 399 A/A. There had significant difference of effective rates between 399 G/G and 399 A/A (P<0.05).

Conclusions

The genotype of XRCC1 Codon 399 may be used in prediction of chemotherapy efficacy for advanced cervical cancer.

表1 XRCC1 Codon 399单核苷酸多态性与晚期宫颈癌化疗疗效的相关性[n(%)]
Table 1 Correlation of single nucleotide polymorphism and chemotherapy effect of late cervical cancer[n(%)]
1
Reguart N, Cardona AF, Carrasco E, et al. BRCA1: A new genomic marker for non-small-cell lung cancer[J]. Clin Lung Cancer, 2008, 9(6): 331-339.
2
洪成雨,徐倩,岳峥,等. 非小细胞肺癌NP方案化疗敏感性与DNA修复基因XRCC1多态性的关系[J]. 癌症,2009, 28(12): 1291-1297.
3
高玉玲,宋保志.宫颈癌新辅助化疗的临床观察[J].海峡药学,2010, 22(12): 257-258.
4
Thompson LH, Brookman KW, Jones NJ, et al. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange[J]. Mol Cell Biol, 1990, 10(12): 6160-6171.
5
Tebbs RS, Flannery ML, Meneses JJ, et al. Requirement for the Xrcc1 DNA base excision repair gene during early mouse development[J]. Dev Biol, 1999, 208(2): 513-529.
6
Thompson LH, West MG. XRCC1 keeps DNA from getting stranded[J]. Mutat Res, 2000, 459(1): 1-18.
7
Siciliano MJ, Carrano AV, Thompson LH. Assignment of a human DNA-repair gene associated with sister-chromatid exchange to chromosome 19[J]. Mutat Res, 1986, 174(4): 303-308.
8
Tahara T, Shibata T, Nakamura M, et al. Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients[J]. Anticancer Res, 2011, 31(2): 705-710.
[1] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[2] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[3] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[4] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[5] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[6] 莫波, 王佩, 王恒, 何志军, 梁俊, 郝志楠. 腹腔镜胃癌根治术与改良胃癌根治术治疗早期胃癌的疗效[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 644-647.
[7] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[8] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[9] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[10] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[11] 邰清亮, 施波, 侍新宇, 陈国梁, 陈俊杰, 武冠廷, 王索, 孙金兵, 顾闻, 叶建新, 何宋兵. 腹腔镜次全结肠切除术治疗顽固性慢传输型便秘的疗效分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 478-483.
[12] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[13] 高显奎, 赵太云, 陆兴俊, 张洪领, 房修罗, 闫碧春, 王胤, 王永翠, 刘苗苗, 冉若男. 内镜电凝止血与组织胶注射治疗上消化道溃疡伴出血的疗效观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 452-455.
[14] 姜里蛟, 张峰, 周玉萍. 多学科诊疗模式救治老年急性非静脉曲张性上消化道大出血患者的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 520-524.
[15] 李莹倩, 李华山. 基于真实世界的完全性直肠脱垂治疗方式评价[J]. 中华临床医师杂志(电子版), 2023, 17(06): 700-705.
阅读次数
全文


摘要